Next Article in Journal
Ionic Liquids—A Review of Their Toxicity to Living Organisms
Next Article in Special Issue
The Footprint of Kynurenine Pathway in Neurodegeneration: Janus-Faced Role in Parkinson’s Disorder and Therapeutic Implications
Previous Article in Journal
Plastic Degradation by Extremophilic Bacteria
Review

Potential Effects of Leukotriene Receptor Antagonist Montelukast in Treatment of Neuroinflammation in Parkinson’s Disease

Laboratory of Translational Neuropharmacology, Department of Clinical Neuroscience, Karolinska Institutet, 17177 Stockholm, Sweden
*
Author to whom correspondence should be addressed.
Academic Editor: Elpida Tsika
Int. J. Mol. Sci. 2021, 22(11), 5606; https://doi.org/10.3390/ijms22115606
Received: 23 April 2021 / Revised: 16 May 2021 / Accepted: 21 May 2021 / Published: 25 May 2021
(This article belongs to the Special Issue Emerging Therapeutic Targets for Parkinson's Disease)
Parkinson’s disease (PD) is a neurodegenerative disorder where misfolded alpha-synuclein-enriched aggregates called Lewy bodies are central in pathogenesis. No neuroprotective or disease-modifying treatments are currently available. Parkinson’s disease is considered a multifactorial disease and evidence from multiple patient studies and animal models has shown a significant immune component during the course of the disease, highlighting immunomodulation as a potential treatment strategy. The immune changes occur centrally, involving microglia and astrocytes but also peripherally with changes to the innate and adaptive immune system. Here, we review current understanding of different components of the PD immune response with a particular emphasis on the leukotriene pathway. We will also describe evidence of montelukast, a leukotriene receptor antagonist, as a possible anti-inflammatory treatment for PD. View Full-Text
Keywords: montelukast; alpha-synuclein; leukotriene; microglia; neuroinflammation; Parkinson’s disease montelukast; alpha-synuclein; leukotriene; microglia; neuroinflammation; Parkinson’s disease
Show Figures

Figure 1

MDPI and ACS Style

Wallin, J.; Svenningsson, P. Potential Effects of Leukotriene Receptor Antagonist Montelukast in Treatment of Neuroinflammation in Parkinson’s Disease. Int. J. Mol. Sci. 2021, 22, 5606. https://doi.org/10.3390/ijms22115606

AMA Style

Wallin J, Svenningsson P. Potential Effects of Leukotriene Receptor Antagonist Montelukast in Treatment of Neuroinflammation in Parkinson’s Disease. International Journal of Molecular Sciences. 2021; 22(11):5606. https://doi.org/10.3390/ijms22115606

Chicago/Turabian Style

Wallin, Johan, and Per Svenningsson. 2021. "Potential Effects of Leukotriene Receptor Antagonist Montelukast in Treatment of Neuroinflammation in Parkinson’s Disease" International Journal of Molecular Sciences 22, no. 11: 5606. https://doi.org/10.3390/ijms22115606

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop